Dr. Thomas Chen
Dr. Chen is a physician, a board certified neurosurgeon and the Director of Surgical Neuro-Oncology at USC. He is highly recognized for his skills as a neurosurgeon, and he is also a tenured- Professor of Neurosurgery and Pathology at USC. Dr. Chen graduated summa cum laude in 3 years from the University of Illinois at Urbana-Champaign, where he also received Bronze Tablet honors (top 3% of undergraduate students) and was inducted into the Phi Beta Kappa national academic honor society.
Neonc Technologies Valuation and Funding
He then attended the University of California, San Francisco, where he was inducted into the Alpha Omega Alpha national medical honor society.
Afterward, he underwent neurosurgery training at USC. In order to prepare for his career in neuro-oncology, Dr. Chen also obtained a PhD degree in pathobiology. His thesis was on the role of immunotherapy in malignant brain tumors. He is also a fellowship-trained spine surgeon and one of a few surgical neuro-oncologists in the country who specialize in spine cancer surgery.
Chen maintains a busy clinical practice in both surgical neuro-oncology and spine surgery. He heads a research laboratory focused on glioma biology.
Neonc Technologies Investors (1)
Dr. Chen has published extensively on glioma biology and neurosurgery. He is on the editorial board for The Spine Journal and is on the review board for Neurosurgery and Journal of Neurosurgery. He is on numerous national neurosurgery committees.
MD, PhD, CEO, CSO
Mr. James F. Walters, also known as Jim, MBA, CPA, serves as the Chief Operating Officer at NeOnc Technologies, Inc.
He serves as Partner in Walters & Skylar, LLP. He has extensive experience in the planning, design, installation and review of financial management information systems. Mr. Walters began his business career in 1976 as an Accountant at Kellogg & Andelson and was its Partner since 1980 and Managing Partner since 1984.
In addition to managing Kellogg & Andelson, he has assisted its clients with the preparation for their initial public offerings, as well as with their acquisition and consolidation strategies. Until 2016, Mr. Walters was Chairman of the Board and responsible for the Overall Management of Kellogg & Andelson Accountancy Corp. In addition, Mr.
Walters has consulted with many middle-sized companies in several different industries. Mr.
Walters has founded, owned and managed companies in Commercial Photography, Corporate Events, Auto Repair and Concrete Molding industries. Mr. Walters serves as a Director of NeOnc Technologies, Inc.
He is a Certified Public Accountant and holds a Masters Degree in Business Administration from Pepperdine University, as well as a Bachelor of Science Degree in Accounting from California State University, Northridge.
MBA, CPA, COO
Walters is a hands-on senior executive with over 25 years experience in finance, accounting and operations of small to medium size companies in a wide range of industries. Since 2001, Patrick has been the President of the Group1, LLC, an advisory firm specializing in small to medium size companies in need of infrastructure and financial restructuring. Patrick usually assumes the Chief Operating Officer or Chief Financial Officer position of these companies and creates disciplined professional management systems to support the success of the company.
From 2005-2007, Patrick was Executive Vice President Finance and Operations for a Shamrock Holdings portfolio company in the luxury magazine publishing business with a national network of 12 city luxury magazines and 13 other publications. During this period, he was instrumental in creating the financial structure that increased the valuation of the company from $54 million to $235 million through the sale of the company to an investor group.
Neonc technologies inc ipo
His other client assignments have included reorganizing the family operations of a Forbes 400 company; structuring an Internet radio stations sales department; setting the business strategy for an Internet global youth portal; reorganizing the infrastructure of an entertainment company; setting up a business lending operation at a financial institution; setting up the reporting structure of a production company; and keeping a global trade association from closing down due to lack of controls over cash and expenditures.
Patrick was employed by Sony Pictures Inc. from 1984 to 2000, holding senior executive positions.
His last title was Senior Vice President, Operations, Worldwide Marketing for Sony Pictures Inc. Patrick started his business career at Deloitte and Touche in Los Angeles and earned his Certified Public Accounting license while in their employ.
He is a graduate from California State University Northridge with a B.A. degree in Economics with a minor in Accounting.
Dr. Simmon has over 30 years of experience growing biotechnology companies and developing products in the biotechnology industry.
Dr. Simmon has served as a Governor of the Emerging Companies Section of BIO (Biotechnology Industrial Organization) and as a director of the Chemical Industries Institute for Toxicology (Research Triangle Park).
He has been CEO, COO, and/or a director of public and private biotechnology companies since 1990, including Alpha 1 Biomedicals, Cortex Pharmaceuticals, Merrimack Pharmaceuticals, and Xytis, Inc.
Currently he is a member of the board of directors of Innovative NeuroTechnologies, Personalized Pharmaceuticals Systems, and Thuris Corporation.
He has personally supervised the submission and acceptance of more than ten INDs.
Ph.D, VP, Chief Regulatory Officer
Dr. Alan Chiang
Dr. Chiang graduated from Kaohsiung Medical College in Taiwan and spent years in Berlin where he earned a PhD degree in neuro-oncology at Free University of Berlin, Germany and also received neurosurgical training at Klinikum Steglitz, FU Berlin.
Afterward, he joined the Department of Neurosurgery, Mackay Memorial Hospital as an attending physician until the present. Dr.
Safety and Efficacy Study in Recurrent Grade IV Glioma
Chiang also spent three years at National Taiwan University and earned his EMBA degree.
Dr. Chiang is active in clinical neurosurgical practice and has interests in brain tumor operation and minimal invasive spine surgery. His major research fields are in molecular biology of brain tumor, esp. in WOX and SHH genes and in biomechanical studies on spine surgery. He has published several articles majorly on brain tumors and spine surgery.
He is a peer reviewer of several international journals and a primary reviewer for research proposals of the Ministry of Science and Technology, Taiwan. He is an international member of American Association of Neurological Surgeons (AANS) and North American Spine Society (NASS) and a fellow of International College of Surgery (FICS).
MD, PhD, EMBA, FICS
Facebook's Initial Public Offering - An IPO Case Study
Davitz is both a medical doctor and a patent lawyer. Prior to starting his practice in patent law, Dr. Davitz was an assistant professor in pathology. He has been able to effectively combine his knowledge of medicine and law into a thriving patent law practice as a partner of Axinn,Veltrop. He is the key advisor for NTIs patent strategy.